HOWL Werewolf Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $44.83M | $56.43M |
| SG&A expense | $15.85M | $19.05M |
| Operating income | -$60.68M | -$73.59M |
| Interest expense | $5.27M | $4.66M |
| Income tax | $0 | — |
| Net income | -$60.82M | -$70.52M |
| EBITDA | -$59.04M | -$71.78M |
| EPS (basic) | -1.32 | -1.63 |
| EPS (diluted) | -1.33 | -1.63 |
| Weighted avg. shares (diluted) | 46.81M | 43.86M |
| Balance sheet | ||
| Cash & equivalents | $57.05M | $112.22M |
| Current assets | $58.59M | $113.07M |
| PP&E, net | $4.69M | $6.32M |
| Total assets | $69.40M | $126.93M |
| Current liabilities | $36.15M | $15.18M |
| Long-term debt | $32.09M | $32.09M |
| Total debt | $32.09M | $32.09M |
| Total liabilities | $44.59M | $53.54M |
| Shareholders' equity | $24.80M | $73.39M |
| Net debt | -$24.96M | -$80.13M |
| Shares outstanding | 48.60M | 44.83M |
| Cash flow statement | ||
| Operating cash flow | -$60.29M | -$56.19M |
| Capital expenditure | $0 | $254,000 |
| Free cash flow | -$60.29M | -$56.44M |
| Investing cash flow | $0 | -$254,000 |
| Financing cash flow | $6.03M | $13.08M |
| Depreciation & amortization | $1.63M | $1.81M |
| Stock-based compensation | $6.25M | $8.83M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.